US equities
|
MU
$913.02
▲+4.04%
TSLA
$394.46
▲+5.98%
SPCX
$148.63
▲+0.78%
NVDA
$216.37
▲+2.56%
META
$631.89
▼-1.67%
AAPL
$342.81
▼-1.41%
SNDK
$1,269.00
▲+2.50%
INTC
$91.97
▲+5.77%
MU
$913.02
▲+4.04%
TSLA
$394.46
▲+5.98%
SPCX
$148.63
▲+0.78%
NVDA
$216.37
▲+2.56%
META
$631.89
▼-1.67%
AAPL
$342.81
▼-1.41%
SNDK
$1,269.00
▲+2.50%
INTC
$91.97
▲+5.77%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Capricor Therapeutics, Inc. - Common Stock
(NQ:
CAPR
)
5.725
-0.205 (-3.46%)
Delayed Quote
Updated: 2:49 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Capricor Therapeutics, Inc. - Common Stock
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
↗
June 20, 2025
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.
Via
Benzinga
Top movers analysis one hour before the close of the markets on 2025-06-20: top gainers and losers in today's session.
↗
June 20, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
June 20, 2025
Via
Benzinga
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
↗
June 20, 2025
Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.
Via
Stocktwits
A Look Ahead: Capricor Therapeutics's Earnings Forecast
↗
May 12, 2025
Via
Benzinga
Gapping stocks in Friday's session
↗
June 20, 2025
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
June 20, 2025
Via
ACCESS Newswire
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
June 20, 2025
Via
Benzinga
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
↗
June 20, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
June 15, 2025
From
Pomerantz LLP
Via
GlobeNewswire
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’
↗
June 11, 2025
Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.
Via
Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
June 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
June 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
June 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
May 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
May 22, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
May 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
May 16, 2025
From
The Schall Law Firm
Via
Business Wire
Forecasting The Future: 5 Analyst Projections For Capricor Therapeutics
↗
May 14, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
May 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Earnings Scheduled For May 13, 2025
↗
May 13, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
May 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
↗
May 07, 2025
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 06, 2025
Via
Benzinga
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic
↗
May 05, 2025
The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August.
Via
Stocktwits
Topics
Economy
Government
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
↗
April 17, 2025
Via
Benzinga
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
↗
April 06, 2025
If CAP-1002 (Deramiocel) is approved on schedule, deramiocel would become the first therapy indicated specifically for DMD-associated cardiomyopathy, addressing a critical unmet need. The StealthX(tm)...
Via
Talk Markets
Topics
Stocks / Equities
FDA Advisory Committee Shakeup and Implications for Capricor Therapeutics
↗
April 01, 2025
Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028).
Via
Talk Markets
Topics
Government
Stocks / Equities
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
March 31, 2025
U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday.
Via
Benzinga
Topics
Stocks
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
